BRPI0923544A2 - anticorpo anti-idiótipos contra um anticorpo contra o peptídeo beta amiloide - Google Patents

anticorpo anti-idiótipos contra um anticorpo contra o peptídeo beta amiloide

Info

Publication number
BRPI0923544A2
BRPI0923544A2 BRPI0923544A BRPI0923544A BRPI0923544A2 BR PI0923544 A2 BRPI0923544 A2 BR PI0923544A2 BR PI0923544 A BRPI0923544 A BR PI0923544A BR PI0923544 A BRPI0923544 A BR PI0923544A BR PI0923544 A2 BRPI0923544 A2 BR PI0923544A2
Authority
BR
Brazil
Prior art keywords
antibody against
amyloid beta
beta peptide
idiotype
idiotype antibody
Prior art date
Application number
BRPI0923544A
Other languages
English (en)
Inventor
Kay-Gunnar Stubenrauch
Rudolf Vogel
Ulrich Essig
Wolfgang Hoesel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0923544A2 publication Critical patent/BRPI0923544A2/pt
Publication of BRPI0923544B1 publication Critical patent/BRPI0923544B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0923544-2A 2008-12-22 2009-12-18 Uso de um anticorpo anti-idiótipo da linhagem celular dsm acc2939 e método para a determinação imunológica de um anticorpo contra o peptídeo beta amiloide em uma amostra BRPI0923544B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08022235.9 2008-12-22
EP08022235 2008-12-22
PCT/EP2009/009160 WO2010072384A1 (en) 2008-12-22 2009-12-18 ANTI-IDIOTYPE ANTIBODY AGAINST AN ANTIBODY AGAINST THE AMYLOID β PEPTIDE

Publications (2)

Publication Number Publication Date
BRPI0923544A2 true BRPI0923544A2 (pt) 2016-01-26
BRPI0923544B1 BRPI0923544B1 (pt) 2021-11-23

Family

ID=40581970

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923544-2A BRPI0923544B1 (pt) 2008-12-22 2009-12-18 Uso de um anticorpo anti-idiótipo da linhagem celular dsm acc2939 e método para a determinação imunológica de um anticorpo contra o peptídeo beta amiloide em uma amostra

Country Status (22)

Country Link
US (2) US8614297B2 (pt)
EP (1) EP2379601B1 (pt)
JP (1) JP5642702B2 (pt)
KR (2) KR20110086182A (pt)
CN (2) CN102257010A (pt)
AR (1) AR074816A1 (pt)
AU (1) AU2009331900A1 (pt)
BR (1) BRPI0923544B1 (pt)
CA (1) CA2746779C (pt)
CY (1) CY1118420T1 (pt)
DK (1) DK2379601T3 (pt)
ES (1) ES2595981T3 (pt)
HR (1) HRP20161398T1 (pt)
HU (1) HUE030478T2 (pt)
IL (1) IL213343A0 (pt)
LT (1) LT2379601T (pt)
MX (2) MX2011006641A (pt)
PL (1) PL2379601T3 (pt)
PT (1) PT2379601T (pt)
SI (1) SI2379601T1 (pt)
TW (1) TWI424162B (pt)
WO (1) WO2010072384A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
TW201348247A (zh) * 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3176580A1 (en) 2015-12-01 2017-06-07 Roche Diagnostics GmbH Method for reduction of interferences in immunoassays
EP3508849B1 (en) * 2016-08-31 2023-04-19 Eiken Kagaku Kabushiki Kaisha Antibody measurement method using antigen-carrying insoluble carrier particles on which antigen is immobilized by different methods, and reagent for antibody measurement
WO2020028266A1 (en) * 2018-08-03 2020-02-06 Cellular Research, Inc. Nuclei barcoding and capture in single cells
EP3969907B1 (en) * 2019-05-13 2025-09-24 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
GB202410666D0 (en) * 2024-07-22 2024-09-04 Micromass Ltd Methods

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219730A (en) 1982-09-28 1993-06-15 New York University Idiotype-anti-idiotype immunoassay
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
EP0170302A1 (fr) 1984-06-27 1986-02-05 l'Association internationale à but scientifique, dite: Institut international de pathologie cellulaire et moléculaire Procédé de dosage immunologique d'une substance dans un échantillon liquide au moyen d'anticorps anti-idiotypiques
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987002778A1 (en) 1985-10-22 1987-05-07 Cooper-Lipotech Solid-phase liposome immunoassay system
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
DE68928994T2 (de) 1988-11-03 1999-12-16 Igen International, Inc. Elektrochemilumineszente testverfahren
WO1990006515A1 (en) 1988-12-09 1990-06-14 Centocor, Inc. Anti-idiotopic immunometric assay
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2003016466A2 (en) 2001-08-17 2003-02-27 Eli Lilly And Company ANTI-Aβ ANTIBODIES
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2005025516A2 (en) 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates
WO2004092197A2 (en) 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CA2543830A1 (en) 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
AU2005290250A1 (en) 2004-07-30 2006-04-06 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
JP4902674B2 (ja) 2006-03-09 2012-03-21 エフ．ホフマン−ラ ロシュ アーゲー 抗薬物抗体アッセイ法
EP1917854A1 (en) 2006-11-06 2008-05-07 F. Hoffmann-La Roche Ag Method for producing anti idiotypic antibodies
US20080127359A1 (en) * 2006-11-06 2008-05-29 Hermann Beck Method for producing anti-idiotypic antibodies
TWI434855B (zh) * 2006-11-21 2014-04-21 Hoffmann La Roche 結合物及其在免疫分析中作為參考標準之用途

Also Published As

Publication number Publication date
PL2379601T3 (pl) 2017-02-28
EP2379601A1 (en) 2011-10-26
JP2012513426A (ja) 2012-06-14
KR20110086182A (ko) 2011-07-27
AU2009331900A1 (en) 2010-07-01
PT2379601T (pt) 2016-10-04
CN102257010A (zh) 2011-11-23
CY1118420T1 (el) 2017-06-28
IL213343A0 (en) 2011-07-31
HUE030478T2 (en) 2017-05-29
SI2379601T1 (sl) 2016-11-30
WO2010072384A1 (en) 2010-07-01
KR20130088199A (ko) 2013-08-07
HRP20161398T1 (hr) 2016-12-16
US8614297B2 (en) 2013-12-24
KR101777899B1 (ko) 2017-09-13
DK2379601T3 (en) 2016-08-29
TW201030335A (en) 2010-08-16
EP2379601B1 (en) 2016-08-10
US9547010B2 (en) 2017-01-17
LT2379601T (lt) 2016-10-25
BRPI0923544B1 (pt) 2021-11-23
CA2746779C (en) 2017-01-24
JP5642702B2 (ja) 2014-12-17
ES2595981T3 (es) 2017-01-04
CN106990251A (zh) 2017-07-28
MX352117B (es) 2017-11-09
US20100167313A1 (en) 2010-07-01
AR074816A1 (es) 2011-02-16
TWI424162B (zh) 2014-01-21
CN106990251B (zh) 2019-12-27
CA2746779A1 (en) 2010-07-01
MX2011006641A (es) 2011-07-12
US20130323762A1 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
IL285226A (en) Anti-n3pglu amyloid beta peptide antibodies and uses thereof
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
SI2379601T1 (sl) Anti-idiotipsko protitelo proti protitelesu proti amiloid beta peptidu
CR10556A (es) Humanized antibody against amyloid beta
DK2177536T3 (da) Antistoffer mod amyloid-beta-peptid
PL2358756T3 (pl) Ludzkie przeciwciała o wysokim powinowactwie wobec pcsk9
BRPI0917148A2 (pt) anticorpos anti-cd5
EP2377932A4 (en) ANTI-Siglec-15 ANTIBODY
ATE543405T1 (de) Frisiergerät
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
BRPI0923359A2 (pt) Anticorpos anti-igf
HRP20170138T1 (hr) Ponovno dobivanje proteina
EP2305405A4 (en) COATED ELEMENT
BRPI0907577A2 (pt) Moduladores para amiloide beta
DK3354267T3 (da) Stabiliseret sulforaphan
IL212175B (en) Muc1* antibodies
DK3118220T3 (da) Protein
BRPI0906799A2 (pt) Moduladores para amiloide beta
EP2109720A4 (en) SELF-STABLE THRUST-SAFETY CLAMP
EP2207803A4 (en) CD9-SPECIFIC HUMAN ANTIBODIES
BRPI0915367A2 (pt) peptídeos e epítopos anti-p2x7
BRPI0814971A2 (pt) Proteína
BRPI0814127A2 (pt) Polipeptídeos imunegênicos e anticorpos monoclonais
EP2348042A4 (en) MODIFIED AMYLOID BETA PEPTIDE
BRPI1011805A2 (pt) anticorpos anti incisura-1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2753 DE 10-10-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.